Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Wainwright

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Sep 16, 2021 3:32pm

166 Views

Post# 33872137

RE:RE:RE:RE:RE:RE:Wainwright

Exactly Magic ... that takes us back to the specific words used ... "Speed bump."

One either believe it's a speed bump or they believe it's a train wreck - that's up to the individual investor. But to make that determination, I'd suggest Xmas Stockings look more to facts than to retail investor sentiment.

How many times have we waited "years" for good companies to become 10-baggers or 20-baggers? Almost every single time.

I know he's already look beyond the price ... otherwise he wouldn't continue to be invested - to come here. He would have move the cash to something else that he really believes in and forgotten all about us. Not so.

: )

---------------

themagicbox wrote: Riiiight...because the phase 2b GI proof of concept study was just imaginary.

The H2S research/platform speaks for itself. The issue now is the delay in monetization of otena. Its the time value of money thats the problem, not the value of the platform itself. Becuase of opportunity cost, people have moved their money elsewhere. Investors will come back once there is a clear direction for otena and negotiations resume.

I get you're butt hurt bagholding but try to stay away from hyperbole.

StockingUp21 wrote:
muggy version 2. How can we negotiate. The platform is worth a cup of cofee right now

themagicbox wrote: Indeed negotiations are key.

Management is more aligned with shareholders given the amalgamation.

MrMugsy wrote: True - I turn specifically to the words used.
There's more information in words than in tone.

Fact is ... we wait for October to get an idea of the direction - low dose and/or high dose pathways.

Getting back to negotiations is what should be top of mind.